Search research articles
Contact Us
Filters
Showing results (1-10 of 109) with videos related to
Page
of 11
Sort By:
Hematology. American Society of Hematology. Education Program
|
December 9, 2023
Cytoreduction for ET and PV: who, what, when, and how?
Douglas Tremblay
Current Treatment Options in Oncology
|
January 14, 2023
New Treatments for Myelofibrosis
Douglas Tremblay, Ruben Mesa
Expert Review of Hematology
|
July 13, 2018
Pacritinib to treat myelofibrosis patients with thrombocytopenia
Douglas Tremblay, John Mascarenhas
Expert Opinion on Emerging Drugs
|
December 7, 2021
Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials
Douglas Tremblay, Ronald Hoffman
Expert Opinion on Pharmacotherapy
|
October 27, 2025
Pharmacologic management of ET: established therapies and emerging agents
Rejowana Rouf, Douglas Tremblay
Future Oncology (London, England)
|
May 23, 2022
Momelotinib for the treatment of myelofibrosis with anemia
Douglas Tremblay, Ruben Mesa
Expert Opinion on Pharmacotherapy
|
March 16, 2023
Pharmacotherapeutic advances for splenomegaly in myelofibrosis
Douglas Tremblay, John Mascarenhas
International Journal of Hematology
|
February 19, 2022
Novel treatments for myelofibrosis: beyond JAK inhibitors
Douglas Tremblay, Ruben Mesa
Therapeutics and Clinical Risk Management
|
July 5, 2023
Emerging Treatment Options for Myelofibrosis: Focus on Anemia
Dahniel Sastow, Douglas Tremblay
Current Hematologic Malignancy Reports
|
February 9, 2020
Novel Therapies in Polycythemia Vera
Douglas Tremblay, John Mascarenhas
Page
of 11
Search research articles
Search
Showing results (1-10 of 109) with videos related to
Sort By:
Page
of 11
Hematology. American Society of Hematology. Education Program
|
December 9, 2023
Cytoreduction for ET and PV: who, what, when, and how?
Douglas Tremblay
Current Treatment Options in Oncology
|
January 14, 2023
New Treatments for Myelofibrosis
Douglas Tremblay, Ruben Mesa
Expert Review of Hematology
|
July 13, 2018
Pacritinib to treat myelofibrosis patients with thrombocytopenia
Douglas Tremblay, John Mascarenhas
Expert Opinion on Emerging Drugs
|
December 7, 2021
Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials
Douglas Tremblay, Ronald Hoffman
Expert Opinion on Pharmacotherapy
|
October 27, 2025
Pharmacologic management of ET: established therapies and emerging agents
Rejowana Rouf, Douglas Tremblay
Future Oncology (London, England)
|
May 23, 2022
Momelotinib for the treatment of myelofibrosis with anemia
Douglas Tremblay, Ruben Mesa
Expert Opinion on Pharmacotherapy
|
March 16, 2023
Pharmacotherapeutic advances for splenomegaly in myelofibrosis
Douglas Tremblay, John Mascarenhas
International Journal of Hematology
|
February 19, 2022
Novel treatments for myelofibrosis: beyond JAK inhibitors
Douglas Tremblay, Ruben Mesa
Therapeutics and Clinical Risk Management
|
July 5, 2023
Emerging Treatment Options for Myelofibrosis: Focus on Anemia
Dahniel Sastow, Douglas Tremblay
Current Hematologic Malignancy Reports
|
February 9, 2020
Novel Therapies in Polycythemia Vera
Douglas Tremblay, John Mascarenhas
Page
of 11